Navigation Links
European Society for Medical Oncology (ESMO) Presents Data from the,Clinical Trial of MediGene's Cancer-Killing Virus in Press,Conference

t of MediGene as of the date of this release. These forward-looking statements are no guarantees for future performance, and the forward-looking events discussed in this press release may not occur. MediGene disclaims any intent or obligation to update any of these forward-looking statements. MediGeneTM is a trademarks of MediGene AG

- ends -

MediGene AG is a publicly quoted (Frankfurt: Prime Standard: MDG) biotechnology company located in Martinsried/Munich, Germany, with subsidiaries in Oxford, UK and San Diego, USA. MediGene is the first German biotech company with a drug on the market. A second drug has been approved by the FDA. A third drug was recently inlicensed to market this drug in Europe. In addition, several drug candidates are currently in clinical development. MediGene also possesses innovative platform technologies.

Contact MediGene AG: Email:

investor@medigene.com

Fax: ++49 - 89 - 85 65 - 2920 Julia Hofmann/Dr. Georg Dönges, Public Relations Tel.: ++49 - 89 - 85 65 - 3317 Dr. Michael Nettersheim, Investor Relations Tel.: ++49 - 89 - 85 65 - 2946



'"/>




Page: 1 2

Related medicine technology :

1. Generex Biotechnology to Make Presentations At 46th Annual Meeting of the European Society of Pediatric Endocrinology
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. DOR BioPharma Announces Issuance of European Patent for Its Oral Multivalent Botulinum Toxin Vaccine BT-VACC
4. The European Myeloma Platform Reports New Survival data for Revlimid Presented at the International Myeloma Workshop in Greece
5. Malvern initiates European user group meetings for chemical imaging
6. PARI Pharma Presents Study Results of Sinus Delivery and Inhaled Liposomal Ciclosporin A at European Cystic Fibrosis Conference
7. Targeted Genetics Reports Inflammatory Arthritis Clinical Data at European Rheumatology Conference
8. Can-Fite Proceeds with Development of Third Drug; Progress in Development of CF502 Will Be Presented at the Annual European Congress of Rheumatology
9. Inspire Announces Presentations at Two European Scientific Conferences
10. Sunesis Pharmaceuticals Reports Positive Data From Studies of Two Anti-Cancer Agents, SNS-595 and SNS-032, at the 12th Congress of the European Hematology Association
11. Archimedes Pharma Presents Positive Efficacy and Safety Data on Nasalfent at European Association for Palliative Care Congress
Post Your Comments:
(Date:12/2/2008)...if., Dec. 2 TorreyPines Therapeuti...e results from a 26 patient Phase II trial evaluat...tomia, or dry mouth, in patients with Sjogren,s sy...istically significant increase in salivary flow pr...0 mg, 15 mg, and 20 mg. These doses were safe and ...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/2/2008)..., Dec. 2 Micromet, Inc. ...eloping novel, proprietary antibodies for the trea...ses, today announced that it has entered into an a...Facility (CEFF) with Kingsbridge Capital Limited, ...e agreement, Kingsbridge has committed to provide ...
(Date:12/1/2008)... 2 New research has fou... computed tomography (CT) scanner in an emergency ...ke victims who receive a potentially life-saving t... Shore Medical Center (NSMC)-Salem Hospital in Sal...eeting of the Radiological Society of North Americ...
Breaking Medicine Technology:TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 2TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 3TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 4TorreyPines Therapeutics Muscarinic Agonist NGX267 Meets Primary Endpoint in a Phase II Clinical Trial in Patients with Xerostomia 5Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Micromet Expands Committed Equity Financing Facility to $75 Million 2Micromet Expands Committed Equity Financing Facility to $75 Million 3Micromet Expands Committed Equity Financing Facility to $75 Million 4Micromet Expands Committed Equity Financing Facility to $75 Million 5Micromet Expands Committed Equity Financing Facility to $75 Million 6Portable CT Increases Chance of Stroke Survival and Recovery 2Portable CT Increases Chance of Stroke Survival and Recovery 3NCPA Applauds U S House Vote in Favor of H R 6331 22698 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 1New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 2New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 3New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 4New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 5New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 6New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 7New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 8New Aptivus 28R 29 28tipranavir 29 Oral Solution Approved for Treatment Experienced Pediatric and Adolescent HIV Patients 6198 9Drug Coated Stents Reduce Repeat Artery Procedures 22693 1Drug Coated Stents Reduce Repeat Artery Procedures 22693 2Drug Coated Stents Reduce Repeat Artery Procedures 22693 3Certain anti cancer agents could be harmful to patients with heart disease 22689 1Certain anti cancer agents could be harmful to patients with heart disease 22689 2Certain anti cancer agents could be harmful to patients with heart disease 22689 3
...ON VALLEY, Pa.--(BUSINESS WIRE)--Apr 12, 2007 - Im...at the American,Association for Cancer Research (A...5 to 18. The Company will feature,Immunicon Pharma...at Kit and the new EasyCount(TM) System at booth 1...opment and clinical,trial testing services to some...
...c found to dramatically reduce the risk of cancer,...estinal stromal,tumors (GIST) , * Patients receivi...c , * Global regulatory submissions planned for us...ollowing surgery to remove,primary tumor , * Glive...ts with,advanced metastatic or inoperable Kit-posi...
Other Medicine Technology:Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 2Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 3Immunicon Will Exhibit CellCapture CTC Mouse/Rat Kit and EasyCount,System for Automated Cell Counting at AACR 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 2Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 3Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 4Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 5Positive Results Prompt US National Cancer Institute to Make Glivec,Available to Patients in Post-Surgical GIST Study 6
(Date:12/2/2008)... Zicam Cold & Flu Companion uses loca...tep ahead of cold and flu. , ...Matrixx Initiatives, Inc., makers of Zicam® Co...® Cold & Flu Companion mobile application ...oid-powered phone. The same mobile application wil...
(Date:12/2/2008)...Call to Action Highlights Need to Reduce Dispariti...nal Efforts , , BETHESDA, Md., Dec. 2 /PRN...s Diseases, (NFID) S.T.O.P. (Share. Teach. Outre...f many of the nation,s leading medical and advocac...to improve adolescent meningococcal vaccination ra...
(Date:12/2/2008)...Dec. 2 MedPro Imaging, a premier p... announced the appointment of three,new ultrasoun... aggressive,expansion. The company also announce...cilities due to substantial growth throughout 2008...e president of Sales and Marketing in,February of...
(Date:12/2/2008)...wellness services available to seniors , , ... Alliance Plan (HAP) is adding acupuncture and chi...Benefit for Medicare Advantage members beginning J...promote wellness encourages Medicare beneficiaries...e putting money back in their wallets. , , ...
Breaking Medicine News(10 mins):Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 2Health News:Zicam Launches "Cold & Flu Companion" Mobile Application 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 2Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 3Health News:NFID Expands Educational Efforts To Reach Racial, Ethnic Families About Dangers of Meningitis 4Health News:MedPro Imaging Continues Aggressive U.S. Expansion 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 2Health News:HAP Expands Medicare Advantage Options to Include Acupuncture and Chiropractic Services 3
...tes in the US are stepping up their efforts to for...ds of mercury emissions.// Throughout the Northe...alth concern. Mercury is a metal that occurs natur...seous form when coal is burned in electrical gener...
...in Rajasthan - is all set to travel to war-hit Leb...ts from the Bhagwan Mahaveer Viklang Sahayta Samit...vitation of the Indian contingent of the UN peacek...SS general secretary S.R. Mehta said. The team w...
...stakes made by medical secretaries in India have b...h hospitals// from being outsourced to India and t...tional Health Service (NHS) have outsourced medica...re considering the option to cut budgetary deficit...
...disease in western Bangladesh's Kushtia district i...ng people// as the number of patients rises everyd... more than 50 people are being treated at the hosp...ents is growing day by day, The Daily Star reporte...
Other Medicine News:Health News:US States Get Ready to Fight Mercury Pollution 2Health News:Jaipur Foot Takes Off for Lebanon 2Health News:Outsourcing of UK Hospital Records to India Opposed 2
Cottle Tenaculum Skin Hook. 5 1/2" small, shallow curve.
Goldman single hook.
Needle tip electrode, davol advantage electrosurgical attachments, 33cm (with extendible outer sheath), non-sterile. These products are supplied non-sterile and must be sterilized before use. Reusabl
The amazingly compact refractor VISUTRON 900+ follows a simple principle: one knob is enough. It offers the user maximal ease, speed, and economics. The quick and silent change of glasses helps the
Medicine Products: